Immune defense against pneumonic plague, Immunological Reviews, vol.26, issue.(Suppl.), pp.256-71, 2008. ,
DOI : 10.1111/j.1600-065X.2008.00674.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804960
Plague, The Lancet, vol.369, issue.9568, pp.1196-207, 2007. ,
DOI : 10.1016/S0140-6736(07)60566-2
An Antigen determining Virulence in Pasteurella pestis, Nature, vol.35, issue.4505, pp.426-433, 1956. ,
DOI : 10.1038/177426b0
The Yersinia Ysc???Yop 'Type III' weaponry, Nature Reviews Molecular Cell Biology, vol.8, issue.10, pp.742-52, 2002. ,
DOI : 10.1038/nrm932
An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge, Vaccine, vol.25, issue.4, pp.741-50, 2007. ,
DOI : 10.1016/j.vaccine.2006.08.010
Oral Vaccination with Salmonella Simultaneously Expressing Yersinia pestis F1 and V Antigens Protects against Bubonic and Pneumonic Plague, The Journal of Immunology, vol.178, issue.2, pp.1059-67, 2007. ,
DOI : 10.4049/jimmunol.178.2.1059
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization, Infect Immun, vol.65, issue.11, pp.4476-82, 1997. ,
F1 and V antigen, FEMS Immunology & Medical Microbiology, vol.51, issue.1, pp.58-69, 2007. ,
DOI : 10.1111/j.1574-695X.2007.00280.x
Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria, Nature Reviews Microbiology, vol.11, issue.5, pp.349-62, 2008. ,
DOI : 10.1002/ijc.22035
Prevention and Treatment of Colitis With Lactococcus lactis Secreting the Immunomodulatory Yersinia LcrV Protein, Gastroenterology, vol.133, issue.3, pp.862-74, 2007. ,
DOI : 10.1053/j.gastro.2007.06.018
Selecting Lactic Acid Bacteria for Their Safety and Functionality by Use of a Mouse Colitis Model, Applied and Environmental Microbiology, vol.72, issue.9, pp.5799-805, 2006. ,
DOI : 10.1128/AEM.00109-06
Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence, Vaccine, vol.20, issue.27-28, pp.27-283304, 2002. ,
DOI : 10.1016/S0264-410X(02)00301-8
Yersinia pseudotuberculosis Harbors a Type IV Pilus Gene Cluster That Contributes to Pathogenicity, Infection and Immunity, vol.70, issue.11, pp.6196-205, 2002. ,
DOI : 10.1128/IAI.70.11.6196-6205.2002
Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague, Proceedings of the National Academy of Sciences, vol.103, issue.14, pp.5526-5556, 2006. ,
DOI : 10.1073/pnas.0509544103
Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria, Vaccine, vol.25, issue.36, pp.6581-6589, 2007. ,
DOI : 10.1016/j.vaccine.2007.06.062
Suppression of cytokines in mice by protein A?V antigen fusion peptide and restoration of synthesis by active immunization, Infect Immun, vol.63, issue.8, pp.3021-3030, 1995. ,
Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis, Vaccine, vol.26, issue.3, pp.316-348, 2008. ,
DOI : 10.1016/j.vaccine.2007.11.028
Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes, Infect Immun, vol.66, issue.2, pp.521-528, 1998. ,
Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A?V antigen fusion peptide, Infect Immun, vol.62, issue.10, pp.4192-201, 1994. ,
Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen, Infect Immun, vol.65, issue.2, pp.446-51, 1997. ,
The Structure of Yersinia pestis V-Antigen, an Essential Virulence Factor and Mediator of Immunity against Plague, Structure, vol.12, issue.2, pp.301-307, 2004. ,
DOI : 10.1016/j.str.2004.01.010